[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:atypical-chronic-myeloid-leukemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":62,"states":63},"Atypical Chronic Myeloid Leukemia",8,7,[8,16,23,30,36,42,49,55],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05549661","Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome\u002FMPN Overlap Neoplasms",[12],"Phase 1","RECRUITING","2026-08-26T02:15:53.461103Z","2026-05-05T02:43:28.622435Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05365035","A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts",[20],"Phase 2","2026-08-26T02:16:21.385056Z","2026-05-05T02:43:27.978920Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05320198","Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia",[27],"Phase 1\u002FPhase 2","2026-08-26T02:18:53.782384Z","2026-07-24T01:27:14.872106Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06523556","Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm\u002FMyelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia",[27],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.949132Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06291987","Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation",[12],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:27.513961Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT03964506","Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant",[46],"Early Phase 1","2026-08-26T02:18:44.395098Z","2026-05-05T02:43:27.480390Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT05350748","Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS",[],"2026-08-26T02:17:05.997056Z","2026-05-13T02:55:06.302096Z",{"nct_id":56,"title":57,"phases":58,"status":59,"updated_at":60,"content_modified":61},"NCT07468916","Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia",[20],"NOT_YET_RECRUITING","2026-08-26T02:17:25.718160Z","2026-05-05T02:43:26.934773Z",[],[]]